SAN FRANCISCO, CA – December 12, 2023 – A groundbreaking new study, known as the WISDOM study, is poised to fundamentally transform breast cancer screening guidelines, proposing a personalized, risk-based approach as a safer and more effective alternative to the long-standing practice of routine annual mammograms for all women. Published today in the prestigious Journal of the American Medical Association (JAMA) and concurrently presented at the San Antonio Breast Cancer Symposium, these pivotal findings suggest that by meticulously tailoring screening frequency to an individual woman’s specific risk profile, it is possible to significantly reduce the incidence of advanced cancer diagnoses while simultaneously ensuring that every person receives the optimal level of screening necessary for their unique circumstances.
The multi-institutional WISDOM study, coordinated by the University of California, San Francisco (UCSF), challenges decades of conventional wisdom that has largely relied on age as the primary determinant for screening frequency. Instead, it champions a sophisticated system built upon a comprehensive evaluation of genetic, biological, and lifestyle factors, along with individual health history and breast density. This paradigm shift, researchers argue, moves the medical community closer to a true era of precision medicine in cancer prevention.
"These findings should not only transform clinical guidelines for breast cancer screening but fundamentally alter clinical practice," asserted Dr. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. "The personalized approach begins with a thorough risk assessment, incorporating a wide array of factors, which can then guide truly effective prevention strategies tailored to the individual."
The Evolution of Screening: A Chronological Imperative for Change
For much of the 20th century, and well into the 21st, breast cancer screening guidelines have largely operated under the assumption that most women face a relatively uniform risk, with age serving as the predominant factor dictating when and how often screening should occur. This one-size-fits-all methodology, typically recommending routine mammograms starting at age 40 or 50, has been the cornerstone of public health campaigns aimed at early detection. However, this generalized approach has faced increasing scrutiny and debate, particularly as advancements in genetic understanding, imaging technology, and risk assessment tools have highlighted the vast heterogeneity of breast cancer risk among women.
The historical rationale behind universal screening was straightforward: early detection improves outcomes. Mammography, introduced widely in the 1970s, became the gold standard. Yet, over time, a deeper understanding of its limitations began to emerge. Concerns about overdiagnosis—the detection of cancers that would never have caused harm in a woman’s lifetime—and the anxiety and costs associated with false positives have fueled calls for a more nuanced strategy. Furthermore, the varying recommendations from different health organizations, such as the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF), underscored a lack of consensus and the need for more robust evidence to guide policy.
It was against this backdrop that the WISDOM study was conceived and launched in 2016. Its ambitious goal was to directly compare the efficacy and safety of traditional annual mammography against a novel, individualized, risk-based screening strategy. The study sought to provide the empirical data necessary to challenge entrenched practices and pave the way for a more intelligent, patient-centric approach. Initial enrollment quickly grew, demonstrating a significant interest from women in participating in a study that promised to redefine their relationship with breast cancer screening.
The first phase of the WISDOM study gathered extensive data from 46,000 women across the United States. Their participation was critical to building the robust evidence base presented in JAMA and at the San Antonio Breast Cancer Symposium on December 12, marking a pivotal moment in the discourse around breast cancer prevention. This publication and presentation signify the culmination of years of dedicated research, meticulous data analysis, and a collaborative effort involving numerous institutions and experts. The findings are not merely incremental adjustments but rather a fundamental re-evaluation of how society approaches one of the most commonly diagnosed cancers among women.
More recently, the WISDOM study has expanded its scope, enrolling over 80,000 women to date, and critically, including participants as young as 30. This expansion reflects a growing recognition that aggressive early-onset cancers, often linked to inherited genetic variants, can affect younger women who would typically fall outside traditional screening windows. This forward-thinking inclusion further underscores the study’s commitment to a truly comprehensive, age-agnostic risk assessment.
Deconstructing the Data: The Efficacy of Precision Screening
The core of the WISDOM study’s revolutionary approach lies in its sophisticated methodology for individual risk assessment. Moving beyond the simplistic reliance on age, researchers employed a battery of well-validated risk models to categorize participants. This comprehensive evaluation factored in a diverse array of data points, including:
- Age: While not the sole factor, age remains a component of the overall risk profile.
- Genetic Information: This includes testing for known pathogenic variants like BRCA1 and BRCA2, as well as the innovative use of polygenic risk scores (PRS). PRS combine information from numerous smaller DNA changes, each contributing a slight increase or decrease in risk, to create a more precise overall genetic risk assessment.
- Lifestyle Factors: Dietary habits, physical activity levels, alcohol consumption, and smoking status are all considered for their known impact on cancer risk.
- Health History: Personal and family history of breast cancer, benign breast conditions, and other relevant medical conditions contribute to the risk profile.
- Breast Density: Women with denser breast tissue have a higher risk of developing breast cancer, and mammograms are also less effective at detecting tumors in dense breasts. This critical factor is therefore integrated into the assessment.
Based on this multi-faceted analysis, participants were assigned to one of four distinct risk categories, each with tailored screening recommendations:
- Lowest Risk Group (26% of participants): These women were advised to delay routine screening until age 50, or until an algorithmic reassessment indicated their individual risk had naturally increased to that of a typical 50-year-old woman. This approach aims to reduce unnecessary screening in a significant portion of the population, mitigating the risks of overdiagnosis and false positives.
- Average Risk Group (62% of participants): For the majority of women, biennial screening (every two years) was recommended. This aligns with certain existing guidelines but is now grounded in a personalized assessment rather than a blanket recommendation.
- Elevated Risk Group (8% of participants): Women in this category were advised to undergo annual mammograms, ensuring closer surveillance for those with a higher statistical likelihood of developing the disease.
- Highest Risk Group (2% of participants): This group, facing the most substantial risk, received the most intensive screening protocol: twice-yearly screening, alternating between mammography and MRI, regardless of their age. This aggressive strategy ensures maximum vigilance for individuals at extreme risk, potentially catching cancers at their earliest, most treatable stages.
Crucially, the study’s findings unequivocally demonstrated that this personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This is a critical validation point, addressing concerns that less frequent screening for lower-risk women might result in missed cancers. Instead, the strategy proved effective in optimizing screening intensity, allocating resources where they are most needed without compromising detection rates.
The acceptance of this personalized approach by participants was remarkably high. Among women who chose not to be randomized into the study’s direct comparison arms, but instead joined an observational group where they could select their preferred screening strategy, a resounding 89% opted for risk-based screening. This strong endorsement from the women directly involved in the study highlights a readiness and willingness within the patient community to embrace more individualized care.
Beyond screening frequency, the WISDOM study also incorporated personalized prevention strategies for women identified as having elevated or highest risk. This included access to a specialized online decision-making tool focused on breast health and direct consultation with a dedicated breast health specialist. Recommendations extended beyond screening to cover actionable lifestyle changes, such as improvements in diet and increased physical activity, alongside discussions about chemopreventive medications known to reduce breast cancer risk. This holistic approach underscores the study’s commitment to proactive health management.
One of the study’s most striking revelations emerged from its comprehensive genetic testing. A significant 30% of women who tested positive for a genetic variant linked to a higher breast cancer risk reported no family history of the disease. Under current clinical guidelines, many of these women would not typically qualify for genetic testing, highlighting a critical gap in existing protocols. This finding alone has profound implications for identifying a substantial number of high-risk individuals who would otherwise remain unaware of their predisposition.
Furthermore, the integration of polygenic risk scores (PRS) proved instrumental in refining risk predictions. By evaluating smaller DNA changes in aggregate, the study improved the precision of individual risk assessments, leading to 12% to 14% of participants being reassigned to a different risk category. This demonstrates the power of advanced genomic tools in enhancing the accuracy of personalized medicine.
Authoritative Voices: Expert Responses and Endorsements
The publication of the WISDOM study has been met with significant enthusiasm from leading experts in oncology and public health, who see its findings as a pivotal moment in the fight against breast cancer.
Dr. Laura J. Esserman, a driving force behind the study, emphasized the transformative potential: "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies. This is about moving from reactive medicine to proactive, preventative care." Her call for a fundamental alteration in clinical practice underscores the profound implications of these findings.
Co-author Dr. Jeffrey A. Tice, a UCSF professor of Medicine specializing in breast cancer risk assessment tools, highlighted the efficiency gains of the new model. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," Dr. Tice stated. This pragmatic perspective points to not only improved patient outcomes but also a more judicious allocation of healthcare resources, a critical consideration in modern healthcare systems.
Allison S. Fiscalini, MPH, director of the Athena Breast Health Network and the WISDOM study at UCSF, drew attention to the pioneering role of the study in genetic testing. "This is one of the first studies to offer genetic testing to all women, regardless of family history," Fiscalini noted. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." Her comments emphasize the study’s forward-thinking integration of genomics into routine screening protocols, pushing the boundaries of conventional medical practice.
The broad consensus among the research team is that the WISDOM study provides compelling evidence that a more nuanced, individualized approach is not only feasible but superior to the blanket recommendations that have characterized breast cancer screening for decades. The positive reception from the scientific community, particularly at a prestigious forum like the San Antonio Breast Cancer Symposium, suggests a growing readiness to embrace these evidence-based changes.
Far-Reaching Implications: Shaping the Future of Breast Health
The implications of the WISDOM study are profound and extend across multiple facets of healthcare, from clinical guidelines and public health policy to patient empowerment and economic considerations.
Impact on Clinical Guidelines and Practice: The most immediate and significant implication is the strong impetus for a re-evaluation and revision of national and international breast cancer screening guidelines. Medical societies and governmental health organizations will face increasing pressure to incorporate individualized risk assessment into their recommendations. This will necessitate changes in how healthcare providers communicate with patients about screening, moving towards a more detailed discussion of personal risk factors rather than simply adhering to age-based protocols. For clinicians, it means integrating comprehensive risk assessment tools, including genetic testing and lifestyle evaluations, into routine practice.
Societal Benefits and Patient Empowerment: For women, this study promises a future of more personalized, less anxiety-inducing breast health management. Lower-risk women may be spared the stress, discomfort, and potential overdiagnosis associated with unnecessary annual mammograms, while higher-risk women will receive the intensive, targeted screening and preventive strategies they truly need. This approach empowers patients by providing them with more accurate information about their individual risk, enabling more informed decision-making in collaboration with their healthcare providers. The high acceptance rate among women in the observational arm of the study clearly indicates a strong patient desire for such tailored care.
Economic Considerations and Resource Allocation: The shift from a universal, age-based model to a risk-stratified one has significant economic implications. By reducing unnecessary screening in a large segment of the population, healthcare resources can be more efficiently reallocated to those at higher risk. This could lead to a more cost-effective screening program overall, even with the increased investment in initial comprehensive risk assessments and genetic testing. The "efficient, effective approach" articulated by Dr. Tice speaks directly to this potential for optimizing healthcare spending while simultaneously improving outcomes.
The Role of Genetic Testing and Precision Medicine: The study’s findings regarding genetic variants, particularly in women without a family history, underscore the critical need to expand access to and awareness of genetic testing. Current guidelines often limit genetic testing to those with a strong family history, meaning a substantial number of high-risk individuals are currently being missed. Integrating universal or more widespread genetic screening, along with polygenic risk scores, into primary care could revolutionize early identification and prevention strategies, aligning perfectly with the broader trends towards precision medicine.
Future Directions: WISDOM 2.0 and Beyond: The WISDOM team is not resting on its laurels. Researchers are actively continuing to refine risk assessment through the WISDOM 2.0 study, which is currently enrolling participants. The ongoing goal is to further enhance the ability to identify women at higher likelihood of developing aggressive breast cancers and to provide them with even more sophisticated screening and prevention strategies tailored to their long-term health needs. This commitment to continuous improvement ensures that the insights gained from WISDOM will continue to evolve and refine breast cancer care for years to come.
The WISDOM study, with its robust data, multi-institutional collaboration, and visionary leadership, marks a pivotal moment in breast cancer prevention. It lays the scientific groundwork for a new era where screening is no longer a generalized directive but a deeply personal, precisely calibrated strategy, moving healthcare closer to its ideal of delivering the right care, to the right person, at the right time.
Co-Authors and Institutions: The extensive list of co-authors from UCSF includes Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD. Other collaborating investigators are from institutions including UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinka Institutet in Stockholm.
Funding for this transformative research was generously provided by the Patient Center Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation, among other contributing sources detailed in the full JAMA publication.
Conflicts of Interest: Dr. Esserman serves as a medical advisory panel member for Blue Cross Blue Shield and has received author fees from the UpToDate electronic medical information resource. Comprehensive disclosures for all investigators are available in the published paper.
About the Author
